Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced seizure and electroencephalographic activity in rats

Epilepsy Research

Volumn 104, Issue 3, 2013, Pages 195-202

  Vilela, Luciano R ^a   Medeiros, Daniel C ^a   Rezende, Gustavo H S ^a   de Oliveira, Antônio Carlos P ^a   Moraes, Marcio F D ^a   Moreira, Fabrício A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Anandamide; Cannabinoids; Epilepsy; Fatty acid amide hydrolase

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID 1 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; PENTETRAZOLE; RIMONABANT;

ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; DISEASE DURATION; ELECTROENCEPHALOGRAPH; EPILEPSY; EPILEPTIC DISCHARGE; HYDROLYSIS; MALE; MYOCLONUS SEIZURE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; SEIZURE THRESHOLD; SIGNAL TRANSDUCTION;

ANIMALS; BENZAMIDES; BENZOXAZINES; CANNABINOIDS; CARBAMATES; CONVULSANTS; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; ENDOCANNABINOIDS; HYDROLYSIS; MALE; MORPHOLINES; NAPHTHALENES; PENTYLENETETRAZOLE; RATS; RATS, WISTAR; SEIZURES;

EID: 84876958493     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.11.006     Document Type: Article

References (53)

1. Alger B.E. Retrograde signaling in the regulation of synaptic transmission, focus on endocannabinoids. Prog. Neurobiol. 2002, 68:247-286.
2. Alger B.E. Endocannabinoids and their implications for epilepsy. Epilepsy Curr. 2004, 4:169-173.
3. Bahremand A., Shafaroodi H., Ghasemi M., Nasrabady S.E., Gholizadeh S., Dehpour A.R. The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice. Epilepsy Res. 2008, 81:44-51.
4. Blair R.E., Deshpande L.S., Sombati S., Elphick M.R., Martin B.R., DeLorenzo R.J. Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy. Neuropharmacology 2009, 57:208-218.
5. Blair R.E., Deshpande L.S., Sombati S., Falenski K.W., Martin B.R., DeLorenzo R.J. Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. J. Pharmacol. Exp. Ther. 2006, 317:1072-1078.
6. Brevard M.E., Kulkarni P., King J.A., Ferris C.F. Imaging the neural substrates involved in the genesis of pentylenetetrazol-induced seizures. Epilepsia 2006, 47:745-754.
7. Chevaleyre V., Takahashi K.A., Castillo P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 2006, 29:37-76.
8. Consroe P.F., Wood G.C., Buchsbaum H. Anticonvulsant nature of marihuana smoking. JAMA 1975, 234:306-307.
9. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384:83-87.
10. Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R., Sanvito W.L., Lander N., Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980, 21:175-185.
11. Deshpande L.S., Blair R.E., Ziobro J.M., Sombati S., Martin B.R., DeLorenzo R.J. Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur. J. Pharmacol. 2007, 558:52-59.
12. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372:686-691.
13. Dichter M.A. Emerging concepts in the pathogenesis of epilepsy and epileptogenesis. Arch. Neurol. 2009, 66:443-447.
14. Echegoyen J., Armstrong C., Morgan R.J., Soltesz I. Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model. Epilepsy Res. 2009, 85:123-127.
15. Ellison J.M., Gelwan E., Ogletree J. Complex partial seizure symptoms affected by marijuana abuse. J. Clin. Psychiatry 1990, 51:439-440.
16. Falenski K.W., Blair R.E., Sim-Selley L.J., Martin B.R., DeLorenzo R.J. Status epilepticus causes a long-lasting redistribution of hippocampal cannabinoid type 1 receptor expression and function in the rat pilocarpine model of acquired epilepsy. Neuroscience 2007, 146:1232-1244.
17. Falenski K.W., Carter D.S., Harrison A.J., Martin B.R., Blair R.E., DeLorenzo R.J. Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus. Brain Res. 2009, 1262:64-72.
18. Fisher R.S., Van Emde Boas W., Blume W., Elger C., Genton P., Lee P., Engel J. Epileptic seizures and epilepsy, definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005, 46:470-472.
19. Gerdeman G.L., Lovinger D.M. Emerging roles for endocannabinoids in long-term synaptic plasticity. Br. J. Pharmacol. 2003, 140:781-789.
20. Gholizadeh S., Shafaroodi H., Ghasemi M., Bahremand A., Sharifzadeh M., Dehpour A.R. Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice. Neuropharmacology 2007, 53:763-770.
21. Goffin K., Van Paesschen W., Van Laere K. In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis. Brain 2011, 134:1033-1040.
22. Jacobs M.P., Leblanc G.G., Brooks-Kayal A., Jensen F.E., Lowenstein D.H., Noebels J.L., Spencer D.D., Swann J.W. Curing epilepsy, progress and future directions. Epilepsy Behav. 2009, 14:438-445.
23. Karanian D.A., Karim S.L., Wood J.T., Williams J.S., Lin S., Makriyannis A., Bahr B.A. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J. Pharmacol. Exp. Ther. 2007, 322:1059-1066.
24. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 2003, 9:76-81.
25. Katona I., Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med. 2008, 14:923-930.
26. Katona I., Sperlagh B., Magloczky Z., Santha E., Kofalvi A., Czirjak S., Mackie K., Vizi E.S., Freund T.F. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 2000, 100:797-804.
27. Katona I., Sperlagh B., Sik A., Kafalvi A., Vizi E.S., Mackie K., Freund T.F. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 1999, 19:4544-4558.
28. Keeler M.H., Reifler C.B. Grand mal convulsions subsequent to marijuana use. Case report. Dis. Nerv. Syst. 1967, 28:474-475.
29. Khanna I.K., Alexander C.W. Fatty acid amide hydrolase inhibitors-progress and potential. CNS Neurol. Disord. Drug Targets 2011, 10:545-558.
30. Klioueva I.A., van Luijtelaar E.L., Chepurnova N.E., Chepurnov S.A. PTZ-induced seizures in rats, effects of age and strain. Physiol. Behav. 2001, 72:421-426.
31. Kozan R., Ayyildiz M., Agar E. The effects of intracerebroventricular AM-251, a CB1-receptor antagonist, and ACEA, a CB1-receptor agonist, on penicillin-induced epileptiform activity in rats. Epilepsia 2009, 50:1760-1767.
32. Loscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011, 20:359-368.
33. Loscher W., Hönack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res. 1991, 8:171-189.
34. Lozsadi D.A., Von Oertzen J., Cock H.R. Epilepsy, recent advances. J. Neurol. 2010, 257:1946-1951.
35. Lutz B. On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem. Pharmacol. 2004, 68:1691-1698.
36. Ma Y.L., Weston S.E., Whalley B.J., Stephens G.J. The phytocannabinoid delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. Br. J. Pharmacol. 2008, 154:204-215.
37. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutierrez S.O., van der Stelt M., Lopez-Rodriguez M.L., Casanova E., Schutz G., Zieglgansberger W., Di Marzo V., Behl C., Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302:84-88.
38. Marsicano G., Lutz B. Neuromodulatory functions of the endocannabinoid system. J. Endocrinol. Invest. 2006, 29:27-46.
39. Monory K., Massa F., Egertova M., Eder M., Blaudzun H., Westenbroek R., Kelsch W., Jacob W., Marsch R., Ekker M., Long J., Rubenstein J.L., Goebbels S., Nave K.A., During M., Klugmann M., Wolfel B., Dodt H.U., Zieglgansberger W., Wotjak C.T., Mackie K., Elphick M.R., Marsicano G., Lutz B. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006, 51:455-466.
40. Moraes M.F., Chavali M., Mishra P.K., Jobe P.C., Garcia-Cairasco N. A comprehensive electrographic and behavioral analysis of generalized tonic-clonic seizures of GEPR-9s. Brain Res. 2005, 1033:1-12.
41. Moreira F.A., Lutz B. The endocannabinoid system, emotion, learning and addiction. Addict. Biol. 2008, 13:196-212.
42. Moreira F.A., Wotjak C.T. Cannabinoids and anxiety. Curr. Top. Behav. Neurosci. 2010, 2:429-450.
43. Naderi N., Ahmad-Molaei L., Aziz Ahari F., Motamedi F. Modulation of anticonvulsant effects of cannabinoid compounds by GABA-A receptor agonist in acute pentylenetetrazole model of seizure in rat. Neurochem. Res. 2011, 36:1520-1525.
44. Naderi N., Ahmad-Molaei L., Mazar-Atabaki A., Ronaghi A., Shirazi-Zand Z., Motiei-Langroudi S.M., Eslahkar S. L-type calcium channel mediates anticonvulsant effect of cannabinoids in acute and chronic murine models of seizure. Neurochem. Res. 2012, 37:279-287.
45. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego. 3rd ed.
46. Pertwee R.G., Howlett A.C., Abood M.E., Alexander S.P., Di Marzo V., Elphick M.R., Greasley P.J., Hansen H.S., Kunos G., Mackie K., Mechoulam R., Ross R.A. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands, beyond CB and CB. Pharmacol. Rev. 2010, 62:588-631.
47. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 2003, 4:873-884.
48. Piomelli D., Tarzia G., Duranti A., Tontini A., Mor M., Compton T.R., Dasse O., Monaghan E.P., Parrott J.A., Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 2006, 12(1):21-38.
49. Shafaroodi H., Samini M., Moezi L., Homayoun H., Sadeghipour H., Tavakoli S., Hajrasouliha A.R., Dehpour A.R. The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice. Neuropharmacology 2004, 47:390-400.
50. Velisek L., Kubova H., Pohl M., Stankova L., Mares P., Schickerova R. Pentylenetetrazol-induced seizures in rats, an ontogenetic study. Naunyn Schmiedebergs Arch. Pharmacol. 1992, 346:588-591.
51. Viveros M.P., Marco E.M., File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol. Biochem. Behav. 2005, 81:331-342.
52. Wallace M.J., Martin B.R., DeLorenzo R.J. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur. J. Pharmacol. 2002, 452:295-301.
53. Wendt H., Soerensen J., Wotjak C.T., Potschka H. Targeting the endocannabinoid system in the amygdala kindling model of temporal lobe epilepsy in mice. Epilepsia 2011, 52:e62-e65.